AEGIR-INSIGHTS
Aegir Insights, a leading provider of decision-making software, data, and intelligence for the offshore wind sector, has raised €8.5M in Series A funding, led by Seaya Andromeda with the participation of Climentum Capital. The company will use the funds to develop the next generation of its web platform, encompassing decision software, data, and intelligence products for the offshore wind industry.
Offshore wind power is among the fastest growing segments within clean energy investments according to the International Renewable Energy Agency (IRENA)’s latest World Energy Transition Outlook (2023), indicating the necessity of offshore wind to grow from today’s 64 GW capacity to 494 GW by 2030 and reach 2,465 GW by 2050.1 However, the project development process remains long and complex, taking as long as 10 years from site identification to commercial operations.
Aegir Insights’ solutions play a crucial role in making data-driven decisions, optimizing development, and reducing costs, thereby accelerating investment in the sector. This is critical in the current environment of cost volatility to ensure optimal capital allocation and project economics. Aegir Insights’ existing client base includes leading developers such as BP, Equinor, and JERA, and it is expanding further into governmental and financial services segments.
The €8.5M in Series A funding will support the development of Aegir Insights’ software-as-a-service (SaaS) platform, data, and intelligence offerings. The company’s technology roadmap includes solutions for simulating price-competitive auctions, streamlined project and portfolio analysis, and broadening functionality to evaluate hybrid assets and system integration. The funding will also enable Aegir Insights to expand its expert client support, serving as a trusted independent advisor.
Aegir Insights was founded in 2020 by CEO Scott Urquhart and CCO Rikke Nørgaard, who, between them, have almost 35 years of energy industry experience working for major renewable energy players, including Ørsted and Vattenfall.
Scott Urquhart, co-founder and CEO of Aegir Insights, said: “We are excited to have found investors with such strong experience in scaling SaaS businesses in the energy sector.” Commenting further on the unique value proposition provided by Seaya Andromeda and Climentum Capital, he said, “Their hands-on experience and renewable sector network will help us accelerate our product roadmap, where we are aiming to set the market standard for offshore wind decision software.”
Rikke Nørgaard, co-founder and CCO of Aegir Insights, added: “Over the past three years, we’ve built a unique product offering, serving offshore wind developers, investors, and governments around the world. This is an important milestone in our journey, both for Aegir Insights as a company and for our clients, that will enable us to enhance our products and mission to accelerate offshore wind deployment.”
Pablo Pedrejon Garcia, Partner at Seaya Andromeda said: “At Seaya Andromeda, we are very excited to partner with Scott and Rikke on the next phase of Aegir’s growth. They have developed a unique solution that is poised to change how investment and planning are done in the offshore wind sector. Under their leadership and considering the huge opportunity within this vertical, we are convinced that Aegir Insights will become the ‘gold standard’ solution for offshore wind decision-making.”
Morten Halborg, Managing Partner at Climentum Capital stated: “In a crowded field of cleantech solutions, Aegir Insights brings clarity with a data-driven software solution. Aegir tackles real-world challenges in the offshore wind industry, offering an integrated platform that will restore profitability while significantly reducing CO2 emissions. Aegir's focus on logic and impact perfectly aligns with our mission to invest in companies that substantially contribute to our CO2 emissions reduction target of 1 million tons annually at fund close.”
Link to press images: https://we.tl/t-aTIeMrlt1E
About Aegir Insights
Smarter, faster, greener.
Aegir Insights is a technology-driven company offering decision-making software, data, and intelligence products for the offshore wind sector. Aegir Insights serves a global client base across corporate, financial, and governmental segments, with product coverage across more than 60 offshore wind markets.
Aegir Insights leverages data science and deep industry experience to help global renewable players make smarter decisions. Its expertise lies in contextualizing complex information through the use of proprietary models developed in close cooperation with industry and academia. Going beyond data, Aegir Insights brings independent strategic insights based on industry experience.
About Seaya Andromeda
Seaya Andromeda is the largest ClimateTech Venture Capital in Southern Europe. With €300M assets under management, Andromeda is an SFDR Article 9 fund on a mission to address global sustainability challenges and deliver profits with purpose through investments in technology-driven companies focusing on Energy & Decarbonisation, the Circular Economy, and the Sustainable Food Value Chain.
Seaya Andromeda is a fund of Seaya – the leading European and Latin American Venture Capital platform, with offices in Madrid, Barcelona, and Mexico City, that invests in exceptional entrepreneurs who are building global technology companies. Seaya raised its first funding in 2013 and currently manages over €700M across five early-stage venture funds. Seaya accelerates the growth of startups by leveraging the founder’s strategic vision, providing them with Seaya’s global platform, its extensive network of founders, investors and multinational corporations, as well as all its experience in the global expansion of companies such as Glovo, Cabify, Wallbox (NYSE:WBX), Spotahome, Clarity AI, Clicars, Alma, and RatedPower.
https://seaya.vc/seaya-andromeda
About Climentum Capital
Climentum Capital is a Venture Capital firm based in Copenhagen, Berlin, and Stockholm. The team invests in European hard-tech startups that cut emissions at the core of industries. The pioneering Article 9 fund has a double incentives structure, with carry indexed on both CO2 emissions reductions and financial returns.
The General Partners Malin Carlström, Dörte Hirschberg, Morten Halborg, and Stefan Mård target late Seed and Series A investments in the five sectors that demonstrate the largest CO2 reduction potential: Energy, Industry, Food, and Agriculture, Buildings, and Transportation. Climentum’s portfolio includes Continuum, Qvantum Industries, Jolt Technologies, Novatron, one.five, and more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213625041/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom